ENLIE Pharmaceutical JSC (HSTC:BCP) EBITDA Margin %: 0.00% (As of . 20)


HSTC:BCP ENLIE Pharmaceutical JSC HSTC:BCP
25 GF Score
Price ₫10,600.00
View Full Analysis

What is ENLIE Pharmaceutical JSC EBITDA Margin %?

ENLIE Pharmaceutical JSC HSTC:BCP 25 EBITDA Margin % is 0.00% as of . 20. GuruFocus rates HSTC:BCP with a GF Score™ of 25/100. Among 955 Drug Manufacturers companies, ENLIE Pharmaceutical JSC ranks worse than 104711.94% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ENLIE Pharmaceutical JSC's EBITDA for the six months ended in . 20 was ₫0.00 Mil. ENLIE Pharmaceutical JSC's Revenue for the six months ended in . 20 was ₫0.00 Mil. Therefore, ENLIE Pharmaceutical JSC's EBITDA margin for the quarter that ended in . 20 was 0.00%.

ENLIE Pharmaceutical JSC  (HSTC:BCP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

ENLIE Pharmaceutical JSC EBITDA Margin % Related Terms

ENLIE Pharmaceutical JSC EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for ENLIE Pharmaceutical JSC's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENLIE Pharmaceutical JSC EBITDA Margin % Chart

ENLIE Pharmaceutical JSC Annual Data
Trend
EBITDA Margin %

ENLIE Pharmaceutical JSC Semi-Annual Data
EBITDA Margin %

HSTC:BCP vs : EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ENLIE Pharmaceutical JSC's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ENLIE Pharmaceutical JSC EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ENLIE Pharmaceutical JSC's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ENLIE Pharmaceutical JSC's EBITDA Margin % falls into.


HSTC:BCP
25GF Score
ENLIE Pharmaceutical JSC HSTC:BCP
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENLIE Pharmaceutical JSC EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ENLIE Pharmaceutical JSC's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

ENLIE Pharmaceutical JSC's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ENLIE Pharmaceutical JSC and its competitors. According to the industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 955 companies in the Drug Manufacturers industry.
Is ENLIE Pharmaceutical JSC's EBITDA Margin % too high?
ENLIE Pharmaceutical JSC's current EBITDA Margin % is 0.00%. Based on the distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ENLIE Pharmaceutical JSC has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENLIE Pharmaceutical JSC's EBITDA Margin % compare to ?
According to the Drug Manufacturers industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 955 companies for EBITDA Margin %. This places ENLIE Pharmaceutical JSC in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ENLIE Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENLIE Pharmaceutical JSC's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENLIE Pharmaceutical JSC stock overvalued right now?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. ENLIE Pharmaceutical JSC's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ENLIE Pharmaceutical JSC (HSTC:BCP), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ENLIE Pharmaceutical JSC Business Description

Comparable Companies
Address NA6 Street, My Phuoc 2 Industrial Park, Ben Cat district, Binh Duong, VNM
ENLIE Pharmaceutical JSC is engaged in the production and trading of pharmaceuticals, medical supplies, cosmetics, foods, and functional foods. It is also engaged in the wholesale of other installation materials and equipment in the construction.
25GF Score

Get the complete analysis for HSTC:BCP

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫10,600.00
Price